XTMAB-16 or Placebo

Preclinical

XXentria, Inc.

XTMAB-16 or Placebo is one of 8 therapeutic programs targeting Pulmonary Sarcoidosis. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[2][1]

Indication

Pulmonary SarcoidosisActive, not recruiting

Pulmonary SarcoidosisPreclinical

Active, not recruiting

Competition

Competitive Landscape

7 competitors in Pulmonary Sarcoidosis

#DrugCompanyPhaseTrials

Trexall

Jazz Pharmaceuticals

Approved

1 2

Plaquenil

Nicorette

Rayos

3 5

Deltasone

PPfizer's Upjohn has merged with Mylan to form Viatris Inc.

Approved

1 6

Efzofitimod

AaTyr Pharma, Inc.

Phase 3

1 7

Glucocorticoid

AbbVie

Preclinical

1 8

XTMAB-16 or Placebo

XXentria, Inc.

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Pulmonary Sarcoidosis1 trial

Study of Multiple-Ascending-Dose Study of XTMAB-16 in Patients With Pulmonary Sarcoidosis With or Without Extrapulmonary Manifestations

Active, not recruiting·XXentria, Inc.·Preclinical·NCT05890729·32 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for XTMAB-16 or Placebo. U.S. National Library of Medicine, National Institutes of Health.
[2]
Open Targets Platform — Drug–disease associations for XTMAB-16 or Placebo. EMBL-EBI & Wellcome Sanger Institute.
[3]
SEC EDGAR — Xentria, Inc. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Highest Phase: Preclinical[1]
Company: XXentria, Inc.

XTMAB-16 or Placebo

Status by Indication[2][1]

Competitive Landscape

Trials by Indication[1]

Pulmonary Sarcoidosis1 trial

References

Drug Info

Quick Facts

Related News